---
title: "Amgen Inc. Stock Outperforms Competitors Despite Losses On The Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292672995.md"
description: "Amgen Inc. (AMGN) shares fell 1.44% to $355.25, marking its fifth consecutive day of losses and closing 9.21% below its 52-week high. Despite the decline, Amgen outperformed competitors Johnson & Johnson, Pfizer, and AbbVie, which also saw declines during a generally positive trading session for major indices. Trading volume remained below the 50-day average."
datetime: "2026-07-14T20:34:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292672995.md)
  - [en](https://longbridge.com/en/news/292672995.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292672995.md)
generator: "portal-rs"
---

# Amgen Inc. Stock Outperforms Competitors Despite Losses On The Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Amgen Inc. (AMGN) shed 1.44% to $355.25 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.38% to 7,543.59 and the Dow Jones Industrial Average rising 0.02% to 52,508.27.

This was the stock's fifth consecutive day of losses.

Amgen Inc. closed 9.21% short of its 52-week high of $391.29, which the company achieved on March 2nd.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) fell 1.52% to $253.85, Pfizer Inc. (PFE) fell 0.94% to $24.25, and AbbVie Inc. (ABBV) fell 1.30% to $244.78.

Trading volume (1.5 M) remained 1.3 million below its 50-day average volume of 2.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 14, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-14-26 1634ET

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Abner Herrman & Brock LLC Decreases Stock Holdings in Amgen Inc. $AMGN](https://longbridge.com/en/news/295293655.md)
- [TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS | AMGN Stock News](https://longbridge.com/en/news/297131330.md)
- [Focus Partners Advisor Solutions LLC Boosts Position in AbbVie Inc. $ABBV](https://longbridge.com/en/news/297140864.md)
- [AstraZeneca's asthma drug Tezspire succeeds in late-stage esophagitis trial](https://longbridge.com/en/news/297134958.md)
- [AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline | ABBV Stock News](https://longbridge.com/en/news/296614126.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**